Canada markets closed

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.80+1.60 (+6.35%)
At close: 4:00PM EST

27.50 +0.70 (2.61%)
After hours: 6:46PM EST

Constellation Pharmaceuticals, Inc.

215 First Street
Suite 200
Cambridge, MA 02142
United States
617 714 0555

Full Time Employees154

Key Executives

NameTitlePayExercisedYear Born
Mr. Jigar RaythathaPres, CEO & Director781.83kN/AN/A
Ms. Emma ReeveChief Financial Officer570.4kN/A1961
Dr. Adrian M. Senderowicz M.D.Sr. Advisor605.9kN/A1964
Dr. Danny ReinbergCo-FounderN/AN/AN/A
Dr. Yang Shi Ph.D.Co-FounderN/AN/AN/A
Dr. David AllisCo-FounderN/AN/AN/A
Mr. Mohan Bala Ph.D.Chief Operating OfficerN/AN/AN/A
Dr. Patrick Trojer Ph.D.Sr. VP & Chief Scientific OfficerN/AN/A1973
Mr. Ronald AldridgeSr. Director of Investor RelationsN/AN/A1954
Kia Khaleghpour Ph.D.VP of Investor Relations & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Corporate Governance

Constellation Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.